How academic labs can approach the drug discovery process as a way to synergize with big pharma.

While the pharmaceutical industry is facing highly challenging times, the academic drug discovery sector has the potential to contribute meaningfully to the discovery of novel drug targets and to the development of new mode-of-action therapeutics against a range of diseases, including rare and neglected diseases.

[1]  S. Rees,et al.  Principles of early drug discovery , 2011, British journal of pharmacology.

[2]  Hans-Joachim Böhm,et al.  A guide to drug discovery: Hit and lead generation: beyond high-throughput screening , 2003, Nature Reviews Drug Discovery.

[3]  R. Schinazi,et al.  Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Giorgio Palù,et al.  Disruption of protein–protein interactions: Towards new targets for chemotherapy , 2005, Journal of cellular physiology.

[5]  A. Loregian,et al.  Selective anti-cytomegalovirus compounds discovered by screening for inhibitors of subunit interactions of the viral polymerase. , 2006, Chemistry & biology.

[6]  C. Tralau-Stewart,et al.  Drug discovery: new models for industry-academic partnerships. , 2009, Drug discovery today.

[7]  Martin Schneider,et al.  Grants4Targets - an innovative approach to translate ideas from basic research into novel drugs. , 2011, Drug discovery today.

[8]  E. De Clercq,et al.  The discovery of antiviral agents: Ten different compounds, ten different stories , 2008, Medicinal research reviews.

[9]  A. Verkman.  Drug discovery in academia. , 2004, American journal of physiology. Cell physiology.

[10]  J. Frearson,et al.  HTS and hit finding in academia – from chemical genomics to drug discovery , 2009, Drug discovery today.

[11]  T. Insel,et al.  NIH Molecular Libraries Initiative , 2004, Science.

[12]  Giorgio Palù,et al.  Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase , 2012, Proceedings of the National Academy of Sciences.

[13]  J. Bryans,et al.  Academia–industry partnerships in drug discovery , 2006, Expert opinion on drug discovery.